GlassScriptPhysician profile
Dylan Winston Boyd
NPI 1891357588
$15,050.98
in general payments reported to CMS, 2019-2025
38 companies · $4,054 in 2025
The $4,054 reported for 2025 was more than what 98% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,198 · 2022: $2,707 · 2023: $3,507 · 2024: $3,584 · 2025: $4,054.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $42.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,103.37 |
| Education | $42.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,082.66 | 2021-2025 | Tezspire, Fasenra, Airsupra |
| Glaxosmithkline, LLC. | $2,038.63 | 2021-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Mylan Specialty L.P. | $1,107.36 | 2021-2024 | Yupelri, Yupelri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $973.35 | 2021-2025 | Ofev, Jascayd, Spiriva Respimat |
| Grifols USA, LLC | $968.63 | 2021-2025 | Prolastin-C Liquid |
| Genzyme Corporation | $743.14 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $558.18 | 2021-2025 | Dupixent |
| United Therapeutics Corporation | $498.54 | 2021-2025 | Tyvaso, Tyvaso |
| Viatris Specialty LLC | $453.96 | 2025 | Yupelri |
| Jazz Pharmaceuticals INC. | $451.01 | 2021-2025 | |
| Electromed, INC. | $422.17 | 2022-2025 | Smartvest |
| Actelion Pharmaceuticals US, INC. | $396.35 | 2021-2023 | Uptravi, Opsumit |
| Baxter Healthcare | $371.85 | 2023-2025 | Hillrom - Life 2000 Ventilation System, Hillrom - Vest System Model 105 Home Care |
| Mallinckrodt Hospital Products INC. | $348.75 | 2021-2025 | Acthar |
| Insmed, INC. | $296.50 | 2021-2025 | Arikayce, Brinsupri |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ani Pharmaceuticals, INC. | $275.67 | 2024-2025 | Purified Cortrophin Gel |
| Merck Sharp & Dohme LLC | $273.42 | 2022-2025 | Zerbaxa, Recarbrio, Winrevair |
| Amgen INC. | $228.34 | 2022-2025 | Tezspire |
| Verona Pharma, INC. | $221.21 | 2025 | Ohtuvayre |
| Shionogi INC | $196.93 | 2021-2025 | Fetroja |
| Axsome Therapeutics, INC. | $163.51 | 2023-2025 | Sunosi |
| Bayer Healthcare Pharmaceuticals INC. | $148.64 | 2021-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $135.46 | 2022-2025 | Glassia |
| Inspire Medical Systems, INC. | $114.04 | 2023-2025 | Inspire |
| Pulmonx Corporation | $97.23 | 2023-2024 | Chartis Catheter, Zephyr Endobronchial Valve, Pulmonx Chartis Tablet Console |
| La Jolla Pharmaceutical Company | $95.02 | 2024-2025 | Giapreza, Zevtera |
| Pfizer INC. | $85.61 | 2021-2025 | |
| Philips North America LLC | $55.44 | 2023 | |
| Avadel Cns Pharmaceuticals, LLC | $42.01 | 2024 | Lumryz |
| Lilly USA, LLC | $33.11 | 2025 | Zepbound |
| Boston Scientific Corporation | $32.27 | 2022-2024 | |
| Genentech USA, INC. | $24.93 | 2022 | |
| 3b Medical, INC. | $24.47 | 2025 | Luna |
| Liquidia Technologies, INC. | $20.07 | 2025 | Yutrepia |
| Harmony Biosciences LLC | $18.88 | 2022 | |
| Abbvie INC. | $18.45 | 2023 | |
| Vifor Pharma, INC. | $17.88 | 2025 | Zemaira |
| Pharming Healthcare, INC. | $17.31 | 2025 | Ruconest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dylan Boyd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.